

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION**, the specification of which is attached hereto and was described and claimed in PCT International Application No. PCT/US02/10764, filed on April 4, 2002.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56. If this is a continuation-in-part application filed under the conditions specified in 35 U.S.C. § 120 which discloses claims and subject matter in addition to that disclosed in the prior copending application, I further acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Number	Country	Day/Month/Year Filed	Claim Priority?
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT international application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Filing Date	Status: patented, pending, abandoned
09/826,115	April 4, 2001	Pending

I hereby grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Combined Declaration and Power of Attorney any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for submitting this document.

Address all telephone calls to Tanya M. Harding, Ph.D. at telephone number (503) 226-7391.

Address all correspondence to the address associated with **Customer Number 24197**, which address is:

Klarquist Sparkman, LLP
121 S.W. Salmon Street, Suite 1600
Portland, OR 97204

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of First or Sole Inventor: Gwong-Jen J. Chang

Residence: Fort Collins, Colorado CO

Mailing Address: 4237 Beaver Creek Drive, Fort Collins, CO 80526

Citizenship: United States of America

Inventor's Signature

Gwong-Jen Chang

Date

July 03, 2004

10 Received 06 AUG 2004

TMH:CRC:dv 07/01/04 6395-64909-02 1-001-01/0
Atty Ref. No. 6395-64909-02

Express Mail Label No. EV352377192US
Date of Deposit: 8/3/04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 10/500,796

Filed: Herewith

Confirmation No. _____

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner:

Art Unit:

Attorney Reference No. 6395-64909-02

MAIL STOP PCT/LEGAL DIVISION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

POWER OF ATTORNEY

Dear Sir:

The assignee of the invention described in the above-referenced application, The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention (as evidenced by the Assignment attached hereto), hereby appoints as its representatives to conduct all business in the Patent and Trademark Office connected therewith the attorneys and agents identified as

Customer No. 24197

all of the law firm of Klarquist Sparkman, LLP, 121 SW Salmon Street, Suite 1600, Portland, Oregon 97204.

Please address all correspondence to Tanya M. Harding, Ph.D., at:


KLARQUIST SPARKMAN, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, OR 97204-2988
Telephone: 503-226-7391
Fax: 503-228-9446

The recorded Assignment referred to in this Substitute Power of Attorney has been reviewed by the undersigned. The undersigned certifies that to the best of the undersigned's knowledge and belief, title is in the assignee.

The Centers for Disease Control and Prevention Technology Transfer Office has been duly delegated responsibility for such patent matters under the authority of the memorandum dated January 31, 1997, from Donna E. Shalala, the Secretary of the Department of Health and Human Services, delegating the authority to the Heads of the Public Health Service Operating Divisions, as well as a memorandum dated October 12, 2000, from Jeffrey P. Koplan, M.D., M.P.H., the Director of the Centers for Disease Control and Prevention (who is a Head of a Public Health Service Operating Division), delegating authority to sign this Power of Attorney to the Associate Director for Science and the Director of the Technology Transfer Office of the Centers for Disease Control and Prevention. The undersigned is authorized to exercise such authority in this matter.

Executed on July 8, 2004, at Atlanta, Georgia.

UNITED STATES DEPARTMENT OF
HEALTH AND HUMAN SERVICES



Andrew Watkins
Director, Technology Transfer Office
Centers for Disease Control and Prevention
(CDC)
1600 Clifton Road NE (E67)
Atlanta, GA 30333
(404) 639-6270